Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Merger 13
Madrigal Pharma and Synta Pharma Merges 13
Licensing Agreements 15
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Equity Offering 17
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 29
Synta Pharma Completes Private Placement Of Shares For US$26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 33
Asset Transactions 35
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Acquisition 36
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc – Key Competitors 37
Madrigal Pharmaceuticals Inc – Key Employees 38
Madrigal Pharmaceuticals Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 06, 2018: Madrigal Pharmaceuticals reports 2018 third quarter 40
Aug 07, 2018: Madrigal Pharmaceuticals reports 2018 second quarter financial results and reviews key clinical achievements 42
May 08, 2018: Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements 45
Mar 13, 2018: Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 47
Nov 09, 2017: Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results 49
Aug 10, 2017: Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results 51
May 11, 2017: Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results 53
Apr 03, 2017: Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196 54
Clinical Trials 56
May 31, 2018: Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial 56
Feb 08, 2018: Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia 58
Jan 30, 2018: Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress 2018 59
Dec 06, 2017: Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial 60
Oct 23, 2017: Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead ß-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting 62
Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 63
Aug 01, 2017: Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH 64
May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196 65
Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Madrigal Pharma and Synta Pharma Merges 13
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 29
Synta Pharma Completes Private Placement Of Shares For US$26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 33
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc, Key Competitors 37
Madrigal Pharmaceuticals Inc, Key Employees 38
Madrigal Pharmaceuticals Inc, Subsidiaries 39
List of Figures
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9